Stamford Pharmaceuticals Inc announces the first patient to be treated with SP-002 in combination with Erivedge® in a Phase 2 Study in locally advanced BCC subjects.

April 10, 2024

Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell...

Read more

Stamford Expands its Scientific Advisory Team

April 1, 2024

Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies, focused on cutaneous and visceral cancers, today announced that...

Read more

Stamford Pharmaceuticals Inc announces Dr Jacques Banchereau at Chief Scientific Officer.

October 1, 2023

Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies focused on cutaneous and visceral cancers, today announced the...

Read more

Stamford Pharmaceuticals Inc has relocated its head office to Austin Texas

May 8, 2023

Stamford Pharmaceuticals Inc, a clinical stage oncology company with a near-term pipeline focused on cutaneous cancer announced today that it...

Read more

Stamford Pharmaceuticals Inc announces amendment and expansion of the ASN-002-003 Phase 2a Study in BCNS and sporadic BCC subjects with up to an addition 5 arms.

April 14, 2023

Stamford Pharmaceuticals Inc, today announced the expansion of its ASN-002-003 Phase 2A study (NCT 04416516). The study performed in collaboration...

Read more